Note sull'episodio
A pediatrics episode on asthma built around single maintenance and reliever therapy, from the April Pediatrics in Review In Brief by Jacobson and Jones, with the diagnostic half from the January issue's comprehensive asthma review. The organizing idea is that the albuterol inhaler we spent decades teaching families to reach for is itself part of the problem — regular short-acting beta agonist use, even for one to two weeks, increases airway hyperresponsiveness and blunts bronchodilator response, and SABA overuse tracks with more exacerbations and higher steroid exposure. SMART inverts the controller-versus-rescue distinction by using one ICS-formoterol inhaler for both. Two things have changed since the April article was written: GINA published a new strategy report in May 2026, and the CARE trial in the Lancet gave us the pediatric randomized evidence the field lacked, showing budesonide-formoterol as sole reliever cut asthma attacks roughly in half against salbutamol in children aged five to fifteen. It closes on the American implementation problem — the regimen is off-label here despite approval in over 120 countries, uptake in adults runs around fifteen percent, and the counseling requires un-teaching what we spent twenty years teaching.